WO2019117252A1 - Eye drop containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid or salt thereof - Google Patents
Eye drop containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid or salt thereof Download PDFInfo
- Publication number
- WO2019117252A1 WO2019117252A1 PCT/JP2018/045895 JP2018045895W WO2019117252A1 WO 2019117252 A1 WO2019117252 A1 WO 2019117252A1 JP 2018045895 W JP2018045895 W JP 2018045895W WO 2019117252 A1 WO2019117252 A1 WO 2019117252A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- eye drop
- salt
- bromobenzoyl
- amino
- container
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
- B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
Definitions
- the present invention relates to an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof.
- 2-amino-3- (4-bromobenzoyl) phenylacetic acid has the following formula (1): It is a compound shown by these.
- the generic name of 2-amino-3- (4-bromobenzoyl) phenylacetic acid is bromfenac, which is known as a non-steroidal anti-inflammatory agent, and in the ophthalmological field as eye drops for the treatment of inflammation in the extraocular and anterior segments It is used.
- eye drops are of a type (multi-dose type eye drops) used several times over a fixed period after opening and a single-use type (unit dose type eye drops).
- multi-dose eye drops generally contain a preservative such as benzalkonium chloride in order to prevent spoilage of the product due to microbial contamination during use.
- Patent Document 1 shows that the aqueous solution composition containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid has storage efficacy and excellent stability by combining bromfenac and benzalkonium chloride. It has been reported that an aqueous liquid composition was prepared. However, no consideration is given to the storage efficacy of the 2-amino-3- (4-bromobenzoyl) phenylacetic acid-containing aqueous solution composition after long-term storage. Also, no consideration or suggestion has been made to examine the form of packaging.
- the present inventors examined the storage efficacy of an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof for a long period of time.
- the problem is that the storage efficacy is not maintained when stored for a long time.
- An object of the present invention is to provide an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof which can maintain preservation efficacy for a long period of time.
- the present inventors conducted intensive studies to maintain the preservation efficacy of eye drops containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof over a long period of time.
- Preservation of an eye drop containing an eye drop containing 3- (4-bromobenzoyl) phenylacetic acid or a salt thereof in an eye drop container and further by tightly packing it with an oxygen scavenger We have found that the efficacy is maintained over a long period of time and completed the present invention.
- the present invention relates to the following.
- the description according to the above (1) or (2), wherein the content of 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof is 0.05 to 0.2% (w / v) Eye drops.
- (10)-(a) The eye drop preparation according to any one of the above (1) to (9), further containing boric acid, borax, sodium edetate hydrate, povidone, and polysorbate 80.
- (10)-(b) The eye drop preparation according to any one of the above (1) to (9), which further contains boric acid, borax, sodium edetate hydrate, povidone, and tyloxapol.
- (11) The eye drop preparation according to any one of the above (1) to (10)-(a) and (10)-(b), wherein the pH is 7.0 to 9.0.
- (12) The eye drop preparation according to any one of the above (1) to (11), which is hermetically packaged in a pillow bag.
- the invention further relates to the following.
- An ophthalmology comprising an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof, an eye drop container containing the eye drop, and a package in which the eye drop container is sealed.
- Pharmaceutical products 17.
- the invention further relates to the following.
- An ophthalmic pharmaceutical product comprising containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof in an eye drop container and further hermetically packaging the eye drop container.
- Production method (19) The method for producing an ophthalmic pharmaceutical product according to the above (18), which is hermetically packaged together with the oxygen scavenger.
- the invention further relates to the following.
- (20) A package in which an eye drop container containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof is sealed.
- (21) The package according to the above (20), wherein the oxygen scavenger is further sealed.
- the invention further relates to the following.
- a method for preserving eye drops which comprises containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof in an eye drop container and further hermetically packaging the eye drop container.
- an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof which can maintain preservation efficacy for a long period of time.
- FIG. 1 is a graph showing the results of the reference test.
- the unit “%” of the content means “w / v%” and is synonymous with “g / 100 mL”.
- eye drop container refers to an eye drop (aqueous composition) containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof in a pharmaceutically acceptable state. That is, it means one containing an eye drop (aqueous composition).
- the term "packaging” means one for containing the eye drop container in the present invention, and is distinguished from the above-mentioned eye drop container.
- “wrapping” means to store (accommodate) the object in the interior of the package, and for example, the object is made of a film by wrapping the object in a film. Including including inside the bag is included.
- “sealing and packaging” means sealing the object inside the package (to make it in a sealed state), for example, after the object is wrapped in a film, the opening of the film bag is made It also includes closing the part and sealing the object inside the bag.
- the closed state includes the airtight state and the closed state.
- preservative efficacy means the preservative effect possessed by eye drops
- maintaining preservative efficacy means that the decay of preservative efficacy with the passage of time of eye drops is suppressed.
- the storage efficacy of the eye drops may be determined based on whether or not the criteria "category IA" is satisfied in the 17th revised Japanese Pharmacopoeia Reference Information "storage efficacy test method".
- the eye drop of the present invention contains 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof (hereinafter referred to as the present compound), is contained in an eye drop container, and is sealed inside the package together with the eye drop container.
- the eye drop of the present invention is, for example, hermetically packaged inside the package together with an oxygen scavenger.
- the eye drop containing the present compound is stored in an eye drop container and further hermetically sealed in the interior of the package, and further hermetically sealed in the interior of the package along with the oxygen scavenger, for a long period of time Maintained.
- the eye drop of the present invention is pharmaceutically stable because the formation of the analogue of the present compound is suppressed over a long period of time.
- the eye drop of the present invention is preferably in a state in which the amount of dissolved oxygen is reduced as much as possible, and it is particularly preferable that the eye drop is substantially free of dissolved oxygen.
- the eye drop of the present invention may be, for example, an eye drop whose storage efficacy is maintained after storage (preservation) for a pharmaceutically acceptable period, for example, 1 to 30 ° C., 75% RH or less After storage for 3 to 36 months under conditions, preferably after storage for 6 months under conditions of 40 ° C., 75% RH or less and / or 12 months under conditions of 25 ° C., 60% RH or less It may be an eye drop whose preservation efficacy is maintained.
- the eye drop of the present invention may be, for example, a pharmaceutically stable eye drop after storage (storage) for a pharmaceutically acceptable period, for example, a condition of 1 to 30 ° C., 40% RH or less. After storage for 12 to 36 months under the medicine, preferably, after 6 months under conditions of 40.degree. C., 25% or less RH and / or after 12 months of storage under 25.degree. C., 60% RH or less Stable eye drops.
- the ophthalmic solution of the present invention contains 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof as an active ingredient (medicinal component), and optionally contains a pharmaceutically acceptable additive.
- the composition is an aqueous composition.
- the property may be, for example, a liquid such as a solution or a suspension, and is preferably an aqueous solution.
- the usable aqueous solvent is not particularly limited as long as it is a solvent containing water, for example, water or a water-soluble solvent such as alcohol or the like and water It may be a mixture, preferably purified water.
- the eye drop and the aqueous composition or the aqueous solvent for producing them are preferably used with the amount of dissolved oxygen reduced as much as possible, and in particular, used substantially free of dissolved oxygen. preferable.
- the means for example, these dissolved by removing dissolved oxygen in the eye drop and the aqueous composition or the aqueous composition for producing them by substitution operation with an inert gas such as nitrogen, argon or the like. The amount of oxygen can be reduced.
- 2-amino-3- (4-bromobenzoyl) phenylacetic acid is non-dissociating 2-amino-3- (4-bromobenzoyl) phenylacetic acid itself, 2-amino-3- (4) Salts of -bromobenzoyl) phenylacetic acid, zwitterions (carboxy groups form carboxylate ions and amino groups form ammonium ions), positive ions (only amino groups form ammonium ions), It can be present in dissolved form as a negative ion (only the carboxy group forms a carboxylate ion).
- the salt of 2-amino-3- (4-bromobenzoyl) phenylacetic acid is not particularly limited as long as it is a pharmaceutically acceptable salt, and as salts, salts with inorganic acids, organic Salts with acids, quaternary ammonium salts, salts with halogen ions, salts with alkali metals, salts with alkaline earth metals, metal salts, salts with organic amines and the like can be mentioned.
- salts with inorganic acids salts with hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, phosphoric acid and the like can be mentioned.
- Examples of quaternary ammonium salts include salts with methyl bromide, methyl iodide and the like.
- Examples of salts with halogen ions include salts with chloride ions, bromide ions, iodide ions and the like, and salts with alkali metals include salts with lithium, sodium, potassium and the like, and alkaline earth metals
- salts with metals, salts with calcium, magnesium and the like can be mentioned, and as metal salts, salts with iron, zinc and the like can be mentioned.
- salts with organic amines triethylenediamine, 2-aminoethanol, 2,2-iminobis (ethanol), 1-deoxy-1- (methylamino) -2-D-sorbitol, 2-amino-2- (hydroxy)
- examples thereof include salts with methyl) -1,3-propanediol, procaine, N, N-bis (phenylmethyl) -1,2-ethanediamine and the like.
- the preferred salt of 2-amino-3- (4-bromobenzoyl) phenylacetic acid is the sodium salt.
- the concentration of 2-amino-3- (4-bromobenzoyl) phenylacetic acid is not particularly limited as long as it is an amount sufficient to exert the desired drug effect, but it is 0.01 to 1.0 % (W / v) is preferable, 0.03 to 0.5% (w / v) is more preferable, 0.05 to 0.2% (w / v) is more preferable, and 0.08 to 0.1 % (W / v) is most preferred.
- the eye drops of the present invention can further contain benzalkonium salts that can be used as additives for pharmaceuticals.
- benzalkonium salts include benzalkonium chloride (BAK), benzalkonium bromide and the like, preferably benzalkonium chloride.
- the upper limit of the concentration of benzalkonium salt in the eyedrops of the present invention is not particularly limited, but is preferably 0.01% (w / v), more preferably 0.008% (w / v), 0.006 % (W / v) is particularly preferred and 0.005% (w / v) is most preferred.
- the lower limit of the concentration is not particularly limited, but preferably 0.0001% (w / v), more preferably 0.0005% (w / v), particularly preferably 0.0008% (w / v), 0.001% (w / v) is most preferred.
- the concentration range is not particularly limited, but is preferably 0.0001% (w / v) or more and 0.01% (w / v) or less, and 0.0005% (w / v) or more and 0.0008% (w) Or less is more preferable, and 0.001% (w / v) or more and 0.006% (w / v) or less is particularly preferable, and 0.001% (w / v) or 0.005% (w / v) Is most preferred.
- the eye drop of the present invention can further contain a sulfite which can be used as an additive of a pharmaceutical.
- a sulfite which can be used as an additive of a pharmaceutical.
- sulfites include sodium sulfite, potassium sulfite, magnesium sulfite, calcium sulfite and the like, with preference given to sodium sulfite.
- sodium sulfite for example, dry sodium sulfite can be used.
- the upper limit of the concentration of sulfite in the eye drop of the present invention is not particularly limited, but is preferably 0.5% (w / v), more preferably 0.3% (w / v), and 0.25% (w / v) w / v) is particularly preferred.
- the lower limit of the concentration is not particularly limited, but is preferably 0.01% (w / v), more preferably 0.03% (w / v), and particularly preferably 0.04% (w / v).
- the concentration range is not particularly limited, but is preferably 0.01% (w / v) or more and 0.5% (w / v) or less, and 0.03% (w / v) or more and 0.3% (w) / V) or less is more preferable, and 0.04% (w / v) or more and 0.25% (w / v) or less is particularly preferable.
- additives such as a buffer, a tonicity agent, a pH adjuster, a stabilizer, a preservative, a solubilizer, a thickening agent and the like to the eye drop of the present invention as necessary.
- the eye drop of the present invention can be incorporated with a buffer that can be used as an additive of a pharmaceutical.
- the buffer include phosphoric acid or a salt thereof, boric acid or a salt thereof, citric acid or a salt thereof, acetic acid or a salt thereof, carbonic acid or a salt thereof, tartaric acid or a salt thereof, ⁇ -aminocaproic acid, trometamol etc. .
- the phosphate examples include sodium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate and the like, and as the borate, borax Sodium borate, potassium borate and the like, and examples of the citrate include sodium citrate and disodium citrate and the like, and examples of the acetate include sodium acetate and potassium acetate and the like; Examples of the tartrate include sodium tartrate, potassium tartrate and the like.
- preferred buffering agents are boric acid or salts thereof, such as boric acid and borax.
- the concentration of the buffer in the eye drop of the present invention can be appropriately adjusted in consideration of the influence on the drug, other additives and / or osmotic pressure ratio, but the total amount thereof is 0.01 to 15% ( w / v) is preferable, 0.05 to 10% (w / v) is more preferable, 0.1 to 6% (w / v) is further preferable, and 0.5 to 5% (w / v) is particularly preferable Preferably, 2 to 4% (w / v) is most preferred.
- an isotonicity agent which can be used as an additive of a medicine can be appropriately blended.
- tonicity agents include ionic tonicity agents and nonionic tonicity agents.
- examples of the ionic tonicity agent include sodium chloride, potassium chloride, calcium chloride, magnesium chloride and the like, and examples of the nonionic tonicity agent include glycerin, propylene glycol, sorbitol, mannitol and the like.
- the preferred tonicity agent is sodium chloride.
- the concentration of the tonicity agent in the eye drop of the present invention can be appropriately adjusted in consideration of the influence on the drug, other additives and / or osmotic pressure ratio, but the total amount thereof is 0.01 to 3 % (W / v) is preferable, 0.02 to 2.5% (w / v) is more preferable, 0.03 to 2% (w / v) is more preferable, and 0.05 to 1% (w / v) v) is particularly preferred, 0.1 to 0.5% (w / v) is most preferred.
- the eye drop preparation of the present invention can contain an appropriate amount of a pH adjuster which can be used as an additive of a pharmaceutical.
- pH adjusters include hydrochloric acid, phosphoric acid, citric acid, acetic acid, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogen carbonate and the like.
- preferred pH adjusters are hydrochloric acid and sodium hydroxide.
- the pH of the eyedrops of the present invention is preferably 7.0 to 9.5, more preferably 7.5 to 9.0, still more preferably 8.0 to 8.6, and most preferably 8.2 to 8.4. preferable.
- a stabilizer that can be used as a pharmaceutical additive can be appropriately blended.
- the stabilizer include edetic acid, sodium edetate, sodium edetate hydrate, sodium citrate, a water-soluble polymer and the like.
- the water-soluble polymer include povidone (polyvinyl pyrrolidone), polyvinyl alcohol, carboxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, sodium polyacrylate and the like.
- preferred stabilizers are sodium edetate hydrate and povidone (preferably povidone (K-30)).
- the concentration of the stabilizer in the eye drop of the present invention can be appropriately adjusted in consideration of the influence on the drug, other additives and / or osmotic pressure ratio, and the total amount thereof is 0.001 to 5% ( w / v) is preferable, 0.002 to 4% (w / v) is more preferable, 0.003 to 3.5% (w / v) is more preferable, and 0.005 to 3.0% (w / v) v) is particularly preferred, 0.01 to 2.2% (w / v) being most preferred.
- a preservative that can be used as a pharmaceutical additive can be appropriately blended.
- preservatives include benzethonium chloride, sorbic acid, potassium sorbate, methyl parahydroxybenzoate, propyl parahydroxybenzoate, chlorobutanol and the like.
- the concentration of the preservative in the eye drop preparation of the present invention can be appropriately adjusted in consideration of the influence on the drug, other additives and / or osmotic pressure ratio, but the total amount thereof is 0.00005 to 0.01 % (W / v) is preferable, 0.0001 to 0.005% (w / v) is more preferable, 0.0002 to 0.004% (w / v) is more preferable, 0.0005 to 0.003 % (W / v) is particularly preferred, and 0.001 to 0.002% (w / v) is most preferred.
- solubilizing agent which can be used as an additive of a medicine can be appropriately blended.
- solubilizers include polysorbate 80, tyloxapol, polyoxyethylene hydrogenated castor oil 60, polyoxyethylene hydrogenated castor oil 40, polyoxyethylene castor oil 35, poloxamer 188, poloxamer 407, macrogol 4000, etc.
- Preferred solubilizers are polysorbate 80 or tyloxapol.
- the concentration of the solubilizing agent in the eye drop of the present invention can be appropriately adjusted in consideration of the influence on the drug, other additives and / or osmotic pressure ratio, and the total amount thereof is 0.001 to 1.
- 0% (w / v) is preferable, 0.005 to 0.5% (w / v) is more preferable, 0.01 to 0.3% (w / v) is more preferable, and 0.01 to 0. 2% (w / v) is particularly preferred and 0.02 to 0.18% (w / v) is most preferred.
- a thickening agent which can be used as an additive of a medicine can be appropriately blended.
- thickening agents include polyvinyl alcohol, carmellose sodium, hydroxyethyl cellulose, hydroxypropyl methylcellulose, methyl cellulose, glucose, glycerin, polyethylene glycol, dextran and the like.
- the concentration of the thickening agent in the eye drop of the present invention can be appropriately adjusted in consideration of the influence on the drug, other additives and / or osmotic pressure ratio, and the total amount thereof is 0.001 to 5 .0% (w / v) is preferable, 0.01 to 2.0% (w / v) is more preferable, 0.05 to 1.0% (w / v) is more preferable, 0.1 to 0 .75% (w / v) is particularly preferred and 0.2 to 0.5% (w / v) is most preferred.
- the eye drop container can accommodate an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof, and is not particularly limited as long as it is pharmaceutically acceptable.
- the eye drop container may be formed of one member or a plurality of members, and may be, for example, a one-piece eye drop container, a two-piece eye drop container, or a three-piece eye drop container.
- a three-piece eye drop container it is formed of three members, a container main body for containing eye drops, an inner plug, and a cap, and integrally molded type in which blow molding and liquid medicine (eye drops) filling are simultaneously performed.
- the eye drop container is formed of a plurality of members, it may be formed of the same material or may be formed of different materials. Furthermore, the material may constitute or coat a part or all of the member.
- polyethylene including LDPE, MDPE, HDPE
- polypropylene polyethylene terephthalate, polybutylene terephthalate, polypropylene-polyethylene copolymer, polyvinyl chloride, acrylic resin, polystyrene, etc.
- polyethylene Can be used preferably polyethylene Can be used.
- the inside of the eye drop container containing the eye drops is preferably in a state in which the amount of oxygen is reduced as much as possible, and it is particularly preferable that the eye drop container contains substantially no oxygen.
- the oxygen amount in the eye drop container can be reduced by removing the oxygen in the eye drop container by substitution operation with an inert gas such as nitrogen, argon or the like.
- the package is not particularly limited as long as it is pharmaceutically acceptable, and may be a regular container such as a bottle, a can, or a box, or an irregular container such as a bag.
- the preferred package is a bag.
- a bag a three-way seal bag, a four-way seal bag, a gusset bag, a pillow bag is mentioned, for example, Preferably, it is a pillow bag.
- a package is not limited to what consists of single layer structure, You may consist of multilayer structures, such as a multilayer film.
- the package may be, for example, a sealed container, an airtight container, or a sealed container.
- the closed container refers to a container capable of preventing solid foreign matter from being mixed in a normal handling, transport or storage state, and preventing the loss of internal ones.
- the airtight container means a container which can prevent the loss of the contents, efflorescence, deliquescence or evaporation without invading solid or liquid foreign matter in the normal handling, transport or storage state.
- a sealed container refers to a container in which gas does not enter under normal handling, transport or storage conditions.
- the inside of the package is preferably in a state in which the amount of oxygen is reduced as much as possible during the hermetic packaging or for a certain period after the hermetic packaging, and particularly preferably substantially free of oxygen.
- the means for example, by sealing the oxygen scavenger inside the package, or prior to sealing, remove oxygen in the package by a substitution operation with an inert gas such as nitrogen, argon or the like.
- an inert gas such as nitrogen, argon or the like.
- substantially free of oxygen in the package means that the oxygen concentration in the gas in the package (container) is zero or very low.
- the oxygen concentration in the gas in the package (container) is, for example, 5% by volume or less, 1% by volume or less, 0.1% by volume or less, 0.01% by volume or less, 0.001% by volume or less, 0.0001 volume It means that it is not more than% and not more than 0.00001% by volume.
- substantially free of dissolved oxygen in the solution means that the concentration of oxygen in the solution is zero or very low, and it is in the oxygen and gas in the solution.
- the oxygen concentration in the gas is, for example, 5% by volume or less, 1% by volume or less, 0.1% by volume or less, 0.01% by volume or less, 0.001% by volume % Or less, 0.0001% by volume or less, or 0.00001% by volume or less.
- the method for measuring the concentration of oxygen in the gas in the package (container) and the concentration of dissolved oxygen in the solution is not particularly limited, and can be measured by a generally known method, for example, using a commercially available measuring device It can be measured according to the method.
- the oxygen concentration in the gas in the package (container) can be measured using a diaphragm electrode type, magnetic type, zirconia type, or other type of oximeter, and the dissolved oxygen concentration in the solution can be determined by titration. It can measure by measuring methods, such as a diaphragm electrode method.
- the material of the package is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include paper, glass, resin and resin film, metal and metal film, etc. Also, a combination of these is used. May be Moreover, as a material of a package, what was only made of paper may be excluded, for example. Specifically, an aluminum film such as an aluminum foil, an aluminum vapor deposition film, an aluminum laminate film and the like can be mentioned. Also, the package may be transparent, translucent or opaque.
- the material of the package is preferably a material having a low oxygen permeability, for example, in order to suppress the inflow of oxygen into the interior of the package, and specifically, the oxygen permeability is 20 ml / m 2 ⁇ atm ⁇ 24 h preferably less, more preferably less 5ml / m 2 ⁇ atm ⁇ 24h , and most preferably not more than 1.5ml / m 2 ⁇ atm ⁇ 24h .
- the package is internally sealed with an eye drop container containing the present compound and optionally an oxygen scavenger, but the others may be further sealed internally, for example, other pharmaceutical and medical products.
- a desiccant such as silica gel, an antioxidant, an insect repellent and the like may be sealed inside.
- the oxygen scavenger is not particularly limited as long as it can reduce the ambient oxygen concentration by absorbing ambient oxygen or reacting with oxygen, for example, metal-based oxygen scavengers such as iron-based oxygen scavengers Organic oxygen scavengers and the like can be used, and preferably, iron-based oxygen scavengers can be used.
- metal-based oxygen scavengers such as iron-based oxygen scavengers
- Organic oxygen scavengers and the like can be used, and preferably, iron-based oxygen scavengers can be used.
- Specific iron-based oxygen scavengers include, for example, Wonder Keep Part Number, RP-30 (registered trademark: Powder Tech Co., Ltd.), Ageless Part Number, ZP-32RY (registered trademark: Mitsubishi Gas Chemical Co., Ltd.), Ever Fresh Part Number, Q-30 (registered trademark: Tori Shige Industry Co., Ltd.) and the like.
- the oxygen scavenger is, for example, sealed inside the package together with the eye drop container containing the present compound, but at this time, the oxygen scavenger is disposed away from the package inside the package Or may be placed in contact with the package.
- the package and the oxygen scavenger are integrated, for example, when the oxygen scavenger is applied to the inner surface of the package, This includes the case where the package has a multilayer structure, and the inner layer or the middle layer is made of an oxygen scavenger.
- the ophthalmic pharmaceutical product of the present invention comprises an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof, an eye drop container containing the eye drop, and the eye drop container sealed.
- An ophthalmic pharmaceutical product comprising a package, and more preferably an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof, and an eye drop container containing the eye drop
- An ophthalmic pharmaceutical product comprising an oxygen scavenger, and the eye drop container and the package sealed with the oxygen scavenger.
- the production method of the present invention comprises containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof in an eye drop container, and further sealing and packaging the eye drop container. It is a manufacturing method, More preferably, an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof is housed in an eye drop container, and the eye drop container is further hermetically packaged together with an oxygen scavenger.
- the ophthalmic pharmaceutical product of the present invention can provide an ophthalmic pharmaceutical product comprising an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof which can maintain preservation efficacy over a long period of time.
- the production method of the present invention can produce an ophthalmologic pharmaceutical product containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof which can maintain storage efficacy for a long period of time.
- the description regarding the above-mentioned eyedrops can be used as it is in these ophthalmic pharmaceutical products and their production methods.
- the package of the present invention is a package in which an eye drop container containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof is sealed, more preferably 2-amino-3
- the package of the present invention can provide a package for sealing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof which can maintain preservation efficacy for a long period of time.
- the description regarding the above-mentioned eyedrops can be used as it is in this package.
- the storage method of the present invention is a method of containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof in an eye drop container and further hermetically packaging the eye drop container,
- an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof is housed in an eye drop container, and the eye drop container is further sealed and packaged together with an oxygen scavenger.
- the storage method of the present invention is also, for example, a method of suppressing the attenuation of the storage efficacy of eye drops and a method of maintaining the storage efficacy of eye drops.
- the above-mentioned description concerning the eye drop can be incorporated as it is.
- test sample In 90 mL of purified water, 0.1 g of sodium 2-amino-3- (4-bromobenzoyl) phenyl acetate (hereinafter referred to as the present compound), 1.1 g of boric acid, and borax 1.1 g, sodium edetate hydrate 0.02 g, povidone (K-30) 2 g, dry sodium sulfite 0.2 g, polysorbate 80 0.15 g, 0.5% benzalkonium chloride solution 1 mL was added and stirred thoroughly.
- aqueous 1 N sodium hydroxide solution was added to adjust the pH to around 8.3, and then an appropriate amount of purified water was added to make the total amount 100 mL, thereby preparing an aqueous composition (eye drops).
- the osmotic pressure of this aqueous composition was about 300 mOsm.
- this aqueous composition is filled in an eye drop container made of polyethylene (PETROTHEN 175K (registered trademark: Tosoh made)), and five of the eye drop containers are AGELESS ZP-32RY (registered trademark: iron-based oxygen absorber).
- PETHEN 175K registered trademark: Tosoh made
- AGELESS ZP-32RY registered trademark: iron-based oxygen absorber
- Mitsubishi Gas Chemical Co., Ltd. pillow-wrapped with an aluminum laminate film (San Aiken Co., Ltd.) with a thickness of about 90 ⁇ m, which has an oxygen permeability of 1.5 ml / m 2 ⁇ atm ⁇ 24 h or less, together with one eye drop container
- One oxygen agent was sealed inside the package. Furthermore, this was put into a paper box and used as a test sample of Example 1.
- Comparative example 1 In the same manner as Example 1, an aqueous composition containing the present compound was prepared and filled in an eye drop container. The product was put into a paper box as it was as a test sample of Comparative Example 1 without pillow packaging with AGELESS (registered trademark).
- AGELESS registered trademark
- Example 1 and Comparative Example 1 are subjected to an accelerated test stored for 6 months under conditions of 40 ° C., 25% RH or less, and performed at the start and end of the accelerated test (at 6 months).
- the storage efficacy of the aqueous composition in Example 1 and Comparative Example 1 was examined.
- the test sample of Example 1 is also subjected to a long-term storage test of storing for 12 months under conditions of 25 ° C. and 40% RH or less, and Example 1 at the start and end of the long-term storage test (at 12 months).
- the storage efficacy of the aqueous composition was also examined. Specifically, the storage efficacy of each aqueous composition was examined by conducting the following storage efficacy test.
- the preservation efficacy test was conducted in accordance with the preservation efficacy test method of the 17th revised Japanese Pharmacopoeia. The following strains were used as inoculum in this test.
- Bacteria Escherichia coli, Escherichia Coli ATCC 8739 (also referred to as E. coli) Pseudomonas aeruginosa ATCC 9027 (also referred to as P. aeruginosa) Staphylococcus aureus, Staphylococcus aureus ATCC 6538 (also referred to as S. aureus) Yeast and mold: Candida albicans ATCC 10231 (also referred to as C. albicans) Aspergillus niger, Aspergillus brasiliensis ATCC 16404 (also referred to as A. brasiliensis)
- Example 1 Aqueous composition in Example 1 and Comparative Example 1 at the start and end of accelerated test (at 6 months) and aqueous composition in Example 1 at the start and end of long-term storage test (at 12 months) As a test sample. Then, the inoculum was inoculated to the test sample such that the concentration of the culture solution in each test sample was 10 5 to 10 6 cells / mL (5 types of bacteria). Specifically, each inoculum is prepared so as to be 10 7 to 10 8 cfu / mL, and the inoculum is inoculated on the test sample so as to be 10 5 to 10 6 cfu / mL. Mixed.
- test results and discussion The test results are shown in Tables 1 and 2.
- the test results in Tables 1 and 2 show the ratio (B / A) of the number of bacteria (B) at the time of inoculation to the number of viable bacteria (A) at the time of examination for each inoculum as a common logarithm value (log reduction value) For example, in the case of “1”, it indicates that the number of viable bacteria at the time of examination has decreased to 10% of the number of inoculated bacteria.
- log reduction value log reduction value
- Example 1 As shown in Tables 1 and 2, the test sample of Example 1 in which the aqueous composition (eye drops) was pillow-packaged, more specifically, pillow-wrapped with an oxygen scavenger, was used not only at the start of the accelerated test, Even at the end of the accelerated test, it exhibited antiseptic effects against all five types of bacteria, and met the criteria of "Category IA" according to the 17th Amended Japanese Pharmacopoeia Reference Information "Preservation Efficacy Test Method". In contrast, the test sample of Comparative Example 1 in which the aqueous composition (eye drops) was not pillow packaged with the oxygen scavenger met the same criteria at the start of the accelerated test, but the preservative effect at the end of the accelerated test.
- Example 1 the test sample of Example 1 in which the aqueous composition (eye drops) was pillow-packaged with an oxygen scavenger met the same standards at the start and end of the long-term storage test, and the storage efficacy was maintained over a long period It turned out that
- Example 1 and Comparative Example 1 were subjected to the above-mentioned accelerated test or long-term storage test to examine changes in the content of bromfenac sodium hydrate and dried sodium sulfite in the aqueous composition during the test. did. Specifically, bromfenac sodium hydrate and dried sodium sulfite contained in the aqueous composition in Example 1 and Comparative Example 1 at the start of the accelerated test and at three and six months after the start of the test, respectively. It quantified by high performance liquid chromatography (HPLC) of the following conditions.
- HPLC high performance liquid chromatography
- benzalkonium chloride and dry sodium sulfite contained in the aqueous composition in Example 1 and Comparative Example 1 at the start of the long-term storage test and at three months, six months and nine months after the start of the test are similarly It was quantified by high performance liquid chromatography (HPLC).
- HPLC high performance liquid chromatography
- the HPLC apparatus used the apparatus made from Waters.
- Tables 3 and 4 show the analysis results of dry sodium sulfite
- Table 4 shows the analysis results of bromfenac sodium hydrate.
- the analysis results in Table 3 and Table 4 show the content of each compound in% after a predetermined period of time after the start of the test, assuming that the content of each compound at the start of the accelerated test or the long-term storage test is 100%.
- this analysis result is an average value of the analysis result of 3 times, respectively.
- Example 3 As shown in Table 3, the test sample of Example 1 in which the aqueous composition (eye drops) was pillow-packaged, more particularly pillow-wrapped with the oxygen scavenger, had its aqueous composition during the accelerated test and the long-term storage test. There was no significant change in the dry sodium sulfite content of the product. On the other hand, in the test sample of Comparative Example 1 in which the aqueous composition (eye drops) was not packaged by pillow, the content of dry sodium sulfite was significantly reduced during the accelerated test and the long-term storage test.
- the aqueous composition (eye drops) containing the present compound is pillow-packaged, more preferably, the aqueous composition (eye-drops) dried sodium sulfite is pillow-wrapped. It was found that the content is better maintained.
- the benzalkonium chloride of the aqueous composition (eyedrops) in the test sample of Example 1 and the test sample of Comparative Example 1 was quantified, the test sample of Example 1 and the test sample of Comparative Example 1 There was no significant change in the benzalkonium content in any of the cases (data not shown).
- Example 4 the test sample of Example 1 in which the aqueous composition (eyedrops) was packaged by pillow, more specifically, the pillow package was packaged with the oxygen scavenger, and the aqueous composition (eyedrops) was packaged by pillow During the accelerated test, none of the test samples of Comparative Example 1 that did not perform significant changes in the content of bromfenac sodium hydrate in the aqueous composition. In addition, in the aqueous composition in Example 1, two kinds of bromfenac analogues (0.05% or more relative to bromfenac sodium hydrate) were produced in the aqueous composition in six months after the initiation of the accelerated test.
- Example 1 By storing the aqueous composition in Example 1 under the condition of 40 ° C./25% RH or less or 25 ° C./40% RH for a certain period, seven types of aqueous compositions having different dry sodium sulfite content were obtained. Then, these aqueous compositions were subjected to storage efficacy test against S. aureus in the same manner as the above-mentioned storage efficacy test. In addition, the content of dry sodium sulfite was quantified in the same manner as the aforementioned quantitative analysis.
- FIG. 1 shows the dry sodium sulfite content of the aqueous composition (in terms of content 0.2 g, expressed as 100%) on the X-axis, the storage efficacy of the aqueous composition (log reduction 7 days after S. aureus inoculation) Value) plotted on the Y axis.
- Formulation example 1 0.1 g of this compound 1.1 g of boric acid Borax 1.1g Edetate sodium hydrate 0.02 g Povidone (K-30) 2g Dry sodium sulfite 0.2g Polysorbate 80 0.15 g Benzalkonium chloride 0.005 g Sodium hydroxide Appropriate amount Purified water Appropriate amount pH 8.3
- Formulation example 2 0.1 g of this compound Polysorbate 80 0.02 g 1.25 g of boric acid Borax 1.0g Edetate sodium hydrate 0.02 g Benzalkonium bromide 0.0016g Hydrochloric acid Appropriate amount Sodium hydroxide Appropriate amount Purified water Appropriate amount pH 8.3
- Formulation example 3 0.1 g of this compound 1.1 g of boric acid Borax 1.1g Edetate sodium hydrate 0.02 g Povidone (K-30) 2g Dry sodium sulfite 0.2g Polysorbate 80 0.15 g 0.001 g of benzalkonium chloride Sodium hydroxide Appropriate amount Purified water Appropriate amount pH 8.3
- Formulation example 4 0.1 g of this compound 1.1 g of boric acid Borax 1.1g Edetate sodium hydrate 0.02 g Povidone (K-30) 2g Dry sodium sulfite 0.2g Tyloxapol 0.02g Benzalkonium chloride 0.005 g Sodium hydroxide Appropriate amount Purified water Appropriate amount pH 8.3
- the blending amounts and blending ratios of the components in the above-mentioned Formulation Examples 1 to 4, that is, the present compound and other additives can be appropriately adjusted.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
- Mechanical Engineering (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
で示される化合物である。2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸の一般名はブロムフェナクであり、非ステロイド性抗炎症剤として知られ、眼科領域においては点眼剤として外眼部及び前眼部の炎症治療に用いられている。 2-amino-3- (4-bromobenzoyl) phenylacetic acid has the following formula (1):
It is a compound shown by these. The generic name of 2-amino-3- (4-bromobenzoyl) phenylacetic acid is bromfenac, which is known as a non-steroidal anti-inflammatory agent, and in the ophthalmological field as eye drops for the treatment of inflammation in the extraocular and anterior segments It is used.
(1)点眼容器に収容された2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤であって、前記点眼容器が、さらに密閉包装されている、点眼剤。
(2)脱酸素剤とともに密閉包装されている、上記(1)記載の点眼剤。
(3)2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩の含有量が、0.05~0.2%(w/v)である、上記(1)または(2)記載の点眼剤。
(4)さらに、ベンザルコニウム塩を含有する、上記(1)~(3)のいずれかに記載の点眼剤。
(5)ベンザルコニウム塩が、ベンザルコニウム塩化物である、上記(4)記載の点眼剤。
(6)ベンザルコニウム塩の含有量が、0.0001~0.01%(w/v)である、上記(4)または(5)記載の点眼剤。
(7)さらに、亜硫酸塩を含有する、上記(1)~(6)のいずれかに記載の点眼剤。
(8)亜硫酸塩が、亜硫酸ナトリウムである、上記(7)記載の点眼剤。
(9)亜硫酸塩の含有量が、0.01~0.5%(w/v)である、上記(7)または(8)記載の点眼剤。
(10)-(a)さらに、ホウ酸、ホウ砂、エデト酸ナトリウム水和物、ポビドン、およびポリソルベート80を含有する、上記(1)~(9)のいずれかに記載の点眼剤。
(10)-(b)さらに、ホウ酸、ホウ砂、エデト酸ナトリウム水和物、ポビドン、およびチロキサポールを含有する、上記(1)~(9)のいずれかに記載の点眼剤。
(11)pHが、7.0~9.0である、上記(1)~(10)-(a)および(10)-(b)のいずれかに記載の点眼剤。
(12)ピロー袋に密閉包装されている、上記(1)~(11)のいずれかに記載の点眼剤。
(13)ピロー袋がアルミフィルムからなる、上記(12)記載の点眼剤。
(14)ピロー袋の酸素透過度が20ml/m2・atm・24h以下である、上記(12)または(13)記載の点眼剤。
(15)脱酸素剤が、鉄系脱酸素剤である、上記(2)~(14)のいずれかに記載の点眼剤。 That is, the present invention relates to the following.
(1) An eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof accommodated in an eye drop container, wherein the eye drop container is further hermetically packaged.
(2) The eye drop preparation according to the above (1), which is hermetically packaged together with the oxygen scavenger.
(3) The description according to the above (1) or (2), wherein the content of 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof is 0.05 to 0.2% (w / v) Eye drops.
(4) The eye drop preparation according to any one of the above (1) to (3), further comprising a benzalkonium salt.
(5) The eye drop preparation according to the above (4), wherein the benzalkonium salt is benzalkonium chloride.
(6) The eye drop preparation according to the above (4) or (5), wherein the content of benzalkonium salt is 0.0001 to 0.01% (w / v).
(7) The eye drop preparation according to any one of the above (1) to (6), which further contains a sulfite.
(8) The eye drop preparation according to the above (7), wherein the sulfite is sodium sulfite.
(9) The eye drop preparation according to the above (7) or (8), wherein the sulfite content is 0.01 to 0.5% (w / v).
(10)-(a) The eye drop preparation according to any one of the above (1) to (9), further containing boric acid, borax, sodium edetate hydrate, povidone, and polysorbate 80.
(10)-(b) The eye drop preparation according to any one of the above (1) to (9), which further contains boric acid, borax, sodium edetate hydrate, povidone, and tyloxapol.
(11) The eye drop preparation according to any one of the above (1) to (10)-(a) and (10)-(b), wherein the pH is 7.0 to 9.0.
(12) The eye drop preparation according to any one of the above (1) to (11), which is hermetically packaged in a pillow bag.
(13) The eye drop preparation according to the above (12), wherein the pillow bag is made of an aluminum film.
(14) The eye drop preparation according to the above (12) or (13), wherein the oxygen permeability of the pillow bag is 20 ml / m 2 · atm · 24 h or less.
(15) The eye drop preparation according to any one of the above (2) to (14), wherein the oxygen scavenger is an iron-based oxygen scavenger.
(16)2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤と、前記点眼剤が収容された点眼容器と、前記点眼容器を密閉した包装とを含む、眼科用医薬製品。
(17)包装が、さらに脱酸素剤を密閉している、上記(16)記載の眼科用医薬製品。 The invention further relates to the following.
(16) An ophthalmology comprising an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof, an eye drop container containing the eye drop, and a package in which the eye drop container is sealed. Pharmaceutical products.
(17) The ophthalmic pharmaceutical product according to the above (16), wherein the package further seals the oxygen scavenger.
(18)2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤を、点眼容器に収容し、前記点眼容器をさらに密閉包装することを含む、眼科用医薬製品の製造方法。
(19)脱酸素剤とともに密閉包装する、上記(18)記載の眼科用医薬製品の製造方法。 The invention further relates to the following.
(18) An ophthalmic pharmaceutical product comprising containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof in an eye drop container and further hermetically packaging the eye drop container. Production method.
(19) The method for producing an ophthalmic pharmaceutical product according to the above (18), which is hermetically packaged together with the oxygen scavenger.
(20)2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤が収容された点眼容器を密閉した、包装。
(21)さらに脱酸素剤を密閉した、上記(20)記載の包装。 The invention further relates to the following.
(20) A package in which an eye drop container containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof is sealed.
(21) The package according to the above (20), wherein the oxygen scavenger is further sealed.
(22)2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤を、点眼容器に収容し、前記点眼容器をさらに密閉包装すること含む、点眼剤の保存方法。
(23)脱酸素剤とともに密閉包装する、上記(22)記載の点眼剤の保存方法。 The invention further relates to the following.
(22) A method for preserving eye drops, which comprises containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof in an eye drop container and further hermetically packaging the eye drop container.
(23) The method for preserving eye drops according to the above (22), which is hermetically packaged together with an oxygen scavenger.
本発明の点眼剤は、2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩(以下、本化合物という)を含有し、点眼容器に収容され、さらに点眼容器ごと包装の内部に密閉包装される。さらには本発明の点眼剤は、例えば、脱酸素剤とともに包装の内部に密閉包装される。本化合物を含有する点眼剤は、点眼容器に収容され、さらに包装の内部に密閉包装されることによって、さらには脱酸素剤とともに包装の内部に密閉包装されることによって、長期間にわたり保存効力が維持される。さらに、本発明の点眼剤は、長期間にわたり本化合物の類縁物質の生成が抑制され、医薬的に安定である。本発明の点眼剤は、その溶存酸素量が出来る限り減少した状態であることが好ましく、特に溶存酸素を実質的に含まないことが好ましい。 <Eye drops>
The eye drop of the present invention contains 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof (hereinafter referred to as the present compound), is contained in an eye drop container, and is sealed inside the package together with the eye drop container. Packaged. Furthermore, the eye drop of the present invention is, for example, hermetically packaged inside the package together with an oxygen scavenger. The eye drop containing the present compound is stored in an eye drop container and further hermetically sealed in the interior of the package, and further hermetically sealed in the interior of the package along with the oxygen scavenger, for a long period of time Maintained. Furthermore, the eye drop of the present invention is pharmaceutically stable because the formation of the analogue of the present compound is suppressed over a long period of time. The eye drop of the present invention is preferably in a state in which the amount of dissolved oxygen is reduced as much as possible, and it is particularly preferable that the eye drop is substantially free of dissolved oxygen.
本発明の点眼剤は、2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を有効成分(薬効成分)として含有し、場合により医薬的に許容される添加物を含有する眼科用組成物であり、水性組成物であることが好ましい。その性状は、例えば、溶液、懸濁液等の液状であることができ、水溶液であることが好ましい。また、本発明の点眼剤が、水性組成物である場合、使用できる水性溶媒は、水を含有する溶媒であれば、特に制限されず、例えば、水、又はアルコール等の水溶性溶媒と水の混合物であってよく、好ましくは精製水である。 (Eyedrops containing the present compound (aqueous composition))
The ophthalmic solution of the present invention contains 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof as an active ingredient (medicinal component), and optionally contains a pharmaceutically acceptable additive. Preferably the composition is an aqueous composition. The property may be, for example, a liquid such as a solution or a suspension, and is preferably an aqueous solution. In addition, when the eye drop of the present invention is an aqueous composition, the usable aqueous solvent is not particularly limited as long as it is a solvent containing water, for example, water or a water-soluble solvent such as alcohol or the like and water It may be a mixture, preferably purified water.
本発明において、点眼容器は、2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸若しくはその塩を含有する点眼剤を収容することができ、医薬的に許容されるものであれば特に限定されない。点眼容器は、1部材又は複数の部材から形成されてよく、例えば、1ピース型点眼容器、2ピース型点眼容器又は3ピース型点眼容器であってよい。ここで、例えば、3ピース型点眼容器であれば、点眼剤を収容する容器本体と中栓、キャップの3部材から形成されるし、ブロー成形と薬液(点眼剤)充填を同時に行う一体成型型容器であれば、その部材数に即して前記点眼容器に含まれる。また、点眼容器が複数の部材から形成される場合には、同一の材質による部材で形成されてもよく、異なる材質による部材で形成されてもよい。さらに、材質が部材の一部又は全部を構成し、又はコーティングしている場合であってもよい。 (Eye drop container)
In the present invention, the eye drop container can accommodate an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof, and is not particularly limited as long as it is pharmaceutically acceptable. . The eye drop container may be formed of one member or a plurality of members, and may be, for example, a one-piece eye drop container, a two-piece eye drop container, or a three-piece eye drop container. Here, for example, in the case of a three-piece eye drop container, it is formed of three members, a container main body for containing eye drops, an inner plug, and a cap, and integrally molded type in which blow molding and liquid medicine (eye drops) filling are simultaneously performed. If it is a container, it will be contained in the said eyedrop container according to the number of members. When the eye drop container is formed of a plurality of members, it may be formed of the same material or may be formed of different materials. Furthermore, the material may constitute or coat a part or all of the member.
本発明において、包装は、医薬的に許容されるものであれば特に制限されず、瓶、缶、箱等の定型容器であってもよいし、袋等の不定形容器であってもよい。本発明において、好ましい包装は袋である。袋としては、例えば、三方シール袋、四方シール袋、ガセット袋、ピロー袋が挙げられ、好ましくは、ピロー袋である。また、包装は、単層構造からなるものに限定されず、多層フィルム等の多層構造からなるものでもよい。 (Packaging)
In the present invention, the package is not particularly limited as long as it is pharmaceutically acceptable, and may be a regular container such as a bottle, a can, or a box, or an irregular container such as a bag. In the present invention, the preferred package is a bag. As a bag, a three-way seal bag, a four-way seal bag, a gusset bag, a pillow bag is mentioned, for example, Preferably, it is a pillow bag. Moreover, a package is not limited to what consists of single layer structure, You may consist of multilayer structures, such as a multilayer film.
本発明において、脱酸素剤は、周囲の酸素を吸収するか又は酸素と反応することで、周囲の酸素濃度を減少できれば特に制限はなく、例えば、鉄系脱酸素剤等の金属系脱酸素剤、有機系脱酸素剤等が使用でき、好ましくは、鉄系脱酸素剤が使用できる。具体的な鉄系脱酸素剤としては、例えば、ワンダーキープ 品番、RP-30(登録商標:パウダーテック株式会社)、エージレス 品番、ZP-32RY(登録商標:三菱ガス化学株式会社)、エバーフレッシュ 品番、Q-30(登録商標:株式会社鳥繁産業)等が挙げられる。 (Oxygen)
In the present invention, the oxygen scavenger is not particularly limited as long as it can reduce the ambient oxygen concentration by absorbing ambient oxygen or reacting with oxygen, for example, metal-based oxygen scavengers such as iron-based oxygen scavengers Organic oxygen scavengers and the like can be used, and preferably, iron-based oxygen scavengers can be used. Specific iron-based oxygen scavengers include, for example, Wonder Keep Part Number, RP-30 (registered trademark: Powder Tech Co., Ltd.), Ageless Part Number, ZP-32RY (registered trademark: Mitsubishi Gas Chemical Co., Ltd.), Ever Fresh Part Number, Q-30 (registered trademark: Tori Shige Industry Co., Ltd.) and the like.
本発明の眼科用医薬製品は、2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤と、前記点眼剤が収容された点眼容器と、前記点眼容器を密閉した包装とを含む、眼科用医薬製品であり、より好ましくは、2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤と、前記点眼剤が収容された点眼容器と、脱酸素剤と、前記点眼容器および前記脱酸素剤を密閉した包装とを含む、眼科用医薬製品である。また、本発明の製造方法は、2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤を、点眼容器に収容し、前記点眼容器をさらに密閉包装することを含む製造方法であり、より好ましくは、2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤を、点眼容器に収容し、前記点眼容器をさらに脱酸素剤とともに密閉包装することを含む製造方法である。本発明の眼科用医薬製品は、長期間にわたり、保存効力を維持できる2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤を含む眼科用医薬製品を提供でき、本発明の製造方法は、長期間にわたり保存効力を維持できる2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤を含む眼科用医薬製品を製造できる。これら眼科用医薬製品およびその製造方法において、前述の点眼剤に関する記述がそのまま援用できる。 <Ophthalmic pharmaceutical product and method for producing the same>
The ophthalmic pharmaceutical product of the present invention comprises an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof, an eye drop container containing the eye drop, and the eye drop container sealed. An ophthalmic pharmaceutical product comprising a package, and more preferably an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof, and an eye drop container containing the eye drop An ophthalmic pharmaceutical product comprising an oxygen scavenger, and the eye drop container and the package sealed with the oxygen scavenger. In addition, the production method of the present invention comprises containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof in an eye drop container, and further sealing and packaging the eye drop container. It is a manufacturing method, More preferably, an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof is housed in an eye drop container, and the eye drop container is further hermetically packaged together with an oxygen scavenger. Manufacturing method including: The ophthalmic pharmaceutical product of the present invention can provide an ophthalmic pharmaceutical product comprising an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof which can maintain preservation efficacy over a long period of time. The production method of the present invention can produce an ophthalmologic pharmaceutical product containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof which can maintain storage efficacy for a long period of time. The description regarding the above-mentioned eyedrops can be used as it is in these ophthalmic pharmaceutical products and their production methods.
本発明の包装は、2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤が収容された点眼容器を密閉した包装であり、より好ましくは、2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤が収容された点眼容器および脱酸素剤を密閉した包装である。本発明の包装は、長期間にわたり保存効力を維持できる2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤を密閉する包装を提供できる。この包装において、前述の点眼剤に関する記述がそのまま援用できる。 <Packaging>
The package of the present invention is a package in which an eye drop container containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof is sealed, more preferably 2-amino-3 An eye drop container containing an eye drop containing (4-bromobenzoyl) phenylacetic acid or a salt thereof and a package in which the oxygen absorber is sealed. The package of the present invention can provide a package for sealing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof which can maintain preservation efficacy for a long period of time. The description regarding the above-mentioned eyedrops can be used as it is in this package.
本発明の保存方法は、2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤を、点眼容器に収容し、前記点眼容器をさらに密閉包装する方法であり、より好ましくは、2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤を、点眼容器に収容し、前記点眼容器をさらに脱酸素剤とともに密閉包装する方法である。この方法により、点眼剤は、医薬的に許容される期間の貯蔵(保存)後において保存効力が維持される。また、本発明の保存方法は、例えば、点眼剤の保存効力の減衰を抑制する方法、点眼剤の保存効力を維持する方法でもある。本発明の保存方法において、前述の点眼剤に関する記述がそのまま援用できる。 <How to save>
The storage method of the present invention is a method of containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof in an eye drop container and further hermetically packaging the eye drop container, Preferably, an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof is housed in an eye drop container, and the eye drop container is further sealed and packaged together with an oxygen scavenger. By this method, the ophthalmic solution maintains its storage efficacy after storage for a pharmaceutically acceptable period. Further, the storage method of the present invention is also, for example, a method of suppressing the attenuation of the storage efficacy of eye drops and a method of maintaining the storage efficacy of eye drops. In the storage method of the present invention, the above-mentioned description concerning the eye drop can be incorporated as it is.
(実施例1)
精製水90mLに、2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸ナトリウム・3/2水和物(以下、本化合物ともいう)を0.1g、ホウ酸を1.1g、ホウ砂を1.1g、エデト酸ナトリウム水和物を0.02g、ポビドン(K-30)を2g、乾燥亜硫酸ナトリウムを0.2g、ポリソルベート80を0.15g、0.5%ベンザルコニウム塩化物溶液を1mL加え、充分に攪拌した。1N水酸化ナトリウム水溶液を加えて、pHを8.3付近とした後、精製水を適量加えて全量を100mLとして水性組成物(点眼剤)を調製した。なお、この水性組成物の浸透圧は、約300mOsmであった。 1. Preparation of test sample (Example 1)
In 90 mL of purified water, 0.1 g of sodium 2-amino-3- (4-bromobenzoyl) phenyl acetate (hereinafter referred to as the present compound), 1.1 g of boric acid, and borax 1.1 g, sodium edetate hydrate 0.02 g, povidone (K-30) 2 g, dry sodium sulfite 0.2 g, polysorbate 80 0.15 g, 0.5% benzalkonium chloride solution 1 mL was added and stirred thoroughly. An aqueous 1 N sodium hydroxide solution was added to adjust the pH to around 8.3, and then an appropriate amount of purified water was added to make the total amount 100 mL, thereby preparing an aqueous composition (eye drops). The osmotic pressure of this aqueous composition was about 300 mOsm.
実施例1と同様にして、本化合物を含有する水性組成物を調製し、点眼容器に充填した。これを、エージレス(登録商標)とともにピロー包装することなく、そのまま紙箱に入れて比較例1の被験サンプルとした。 (Comparative example 1)
In the same manner as Example 1, an aqueous composition containing the present compound was prepared and filled in an eye drop container. The product was put into a paper box as it was as a test sample of Comparative Example 1 without pillow packaging with AGELESS (registered trademark).
実施例1及び比較例1の被験サンプルについて、40℃、25%RH以下の条件で6ヵ月保存する加速試験を行い、加速試験開始時及び終了時(6ヵ月経過時)での実施例1及び比較例1における水性組成物の保存効力を検討した。また、実施例1の被験サンプルについては、25℃、40%RH以下の条件で12ヵ月保存する長期保存試験も行い、長期保存試験開始時及び終了時(12ヵ月経過時)での実施例1における水性組成物の保存効力についても検討した。具体的には、以下の保存効力試験を行うことで、それぞれの水性組成物の保存効力を検討した。 2. Storage efficacy test The test samples of Example 1 and Comparative Example 1 are subjected to an accelerated test stored for 6 months under conditions of 40 ° C., 25% RH or less, and performed at the start and end of the accelerated test (at 6 months). The storage efficacy of the aqueous composition in Example 1 and Comparative Example 1 was examined. In addition, the test sample of Example 1 is also subjected to a long-term storage test of storing for 12 months under conditions of 25 ° C. and 40% RH or less, and Example 1 at the start and end of the long-term storage test (at 12 months). The storage efficacy of the aqueous composition was also examined. Specifically, the storage efficacy of each aqueous composition was examined by conducting the following storage efficacy test.
保存効力試験は、第十七改正日本薬局方の保存効力試験法に準拠して行なった。本試験では、接種菌として以下の菌株を使用した。
細菌:
大腸菌,Escherichia Coli ATCC 8739(E.coliともいう)
緑膿菌,Pseudomonas aeruginosa ATCC 9027(P.aeruginosaともいう)
黄色ブドウ球菌,Staphylococcus aureus ATCC 6538(S.aureusともいう)
酵母菌及びカビ類:
カンジダ,Candida albicans ATCC 10231(C.albicansともいう)
クロコウジカビ,Aspergillus brasiliensis ATCC16404(A.brasiliensisともいう) (Conservative efficacy test method)
The preservation efficacy test was conducted in accordance with the preservation efficacy test method of the 17th revised Japanese Pharmacopoeia. The following strains were used as inoculum in this test.
Bacteria:
Escherichia coli, Escherichia Coli ATCC 8739 (also referred to as E. coli)
Pseudomonas aeruginosa ATCC 9027 (also referred to as P. aeruginosa)
Staphylococcus aureus, Staphylococcus aureus ATCC 6538 (also referred to as S. aureus)
Yeast and mold:
Candida albicans ATCC 10231 (also referred to as C. albicans)
Aspergillus niger, Aspergillus brasiliensis ATCC 16404 (also referred to as A. brasiliensis)
試験結果を表1及び表2に示す。表1及び表2の試験結果は、各接種菌に対する検査時の生菌数(A)に対する接種時の菌数(B)の比(B/A)を常用対数値(対数減少値)で示しており、例えば「1」の場合には、検査時の生菌数が接種菌数の10%に減少したことを示している。また、第十七改正日本薬局方 参考情報「保存効力試験法」による基準「カテゴリーIA」の基準に適合するか否かを判定した。 (Test results and discussion)
The test results are shown in Tables 1 and 2. The test results in Tables 1 and 2 show the ratio (B / A) of the number of bacteria (B) at the time of inoculation to the number of viable bacteria (A) at the time of examination for each inoculum as a common logarithm value (log reduction value) For example, in the case of “1”, it indicates that the number of viable bacteria at the time of examination has decreased to 10% of the number of inoculated bacteria. In addition, it was determined whether or not the standard of “category IA” according to the “The storability effect test method” of the 17th revised Japanese Pharmacopoeia reference information is met.
実施例1及び比較例1の被験サンプルについて、前述の加速試験又は長期保存試験を行い、試験中における水性組成物のブロムフェナクナトリウム水和物及び乾燥亜硫酸ナトリウムの含有量の変化を検討した。具体的には、加速試験開始時並びに試験開始後3ヵ月及び6ヵ月経過時での実施例1及び比較例1における水性組成物に含まれるブロムフェナクナトリウム水和物及び乾燥亜硫酸ナトリウムを、それぞれ、下記条件の高速液体クロマトグラフィー(HPLC)により定量した。また、長期保存試験開始時並びに試験開始後3ヵ月、6ヵ月及び9ヵ月経過時での実施例1及び比較例1における水性組成物に含まれるベンザルコニウム塩化物及び乾燥亜硫酸ナトリウムを、同様に高速液体クロマトグラフィー(HPLC)により定量した。なお、HPLC装置は、Waters社製の装置を使用した。 3. Quantitative Analysis The test samples of Example 1 and Comparative Example 1 were subjected to the above-mentioned accelerated test or long-term storage test to examine changes in the content of bromfenac sodium hydrate and dried sodium sulfite in the aqueous composition during the test. did. Specifically, bromfenac sodium hydrate and dried sodium sulfite contained in the aqueous composition in Example 1 and Comparative Example 1 at the start of the accelerated test and at three and six months after the start of the test, respectively. It quantified by high performance liquid chromatography (HPLC) of the following conditions. In addition, benzalkonium chloride and dry sodium sulfite contained in the aqueous composition in Example 1 and Comparative Example 1 at the start of the long-term storage test and at three months, six months and nine months after the start of the test are similarly It was quantified by high performance liquid chromatography (HPLC). In addition, the HPLC apparatus used the apparatus made from Waters.
検出器:電気伝導度計
カラム:Shodex IC I-524A(12μm、4.6mm×100mm、昭和電工社製)
カラム温度:50℃付近の一定温度
移動相:0.25mM p-ヒドロキシ安息香酸/1.2mM ジエチルアミノエタノール/水溶液
流量:約1.5mL/min.
分析時間:20分 (Dry sodium sulfite determination conditions)
Detector: conductivity meter column: Shodex IC I-524A (12 μm, 4.6 mm × 100 mm, manufactured by Showa Denko)
Column temperature: constant temperature mobile phase around 50 ° C .: 0.25 mM p-hydroxybenzoic acid / 1.2 mM diethylaminoethanol / aqueous solution flow rate: about 1.5 mL / min.
Analysis time: 20 minutes
検出器:紫外吸光光度計(測定波長:266nm)
カラム:XBridge C18(5μm、4.6×250mm、Waters社製)
カラム温度:40℃付近の一定温度
移動相A:20mMリン酸緩衝液pH7.3/アセトニトリル(75/25)
移動相B:20mMリン酸緩衝液pH7.3/アセトニトリル(30/70)
グラジエント条件:0%B(0min)-0%B(30min)-90%B(60min)
流量:約1.0mL/min.
分析時間:70分 (Condition of determination of bromfenac sodium hydrate)
Detector: Ultraviolet absorptiometer (measurement wavelength: 266 nm)
Column: X Bridge C18 (5 μm, 4.6 × 250 mm, manufactured by Waters)
Column temperature: Constant temperature around 40 ° C. Mobile phase A: 20 mM phosphate buffer pH 7.3 / acetonitrile (75/25)
Mobile phase B: 20 mM phosphate buffer pH 7.3 / acetonitrile (30/70)
Gradient condition: 0% B (0 min)-0% B (30 min)-90% B (60 min)
Flow rate: about 1.0 mL / min.
Analysis time: 70 minutes
定量分析の結果を表3及び表4に示す。表3は、乾燥亜硫酸ナトリウム、表4は、ブロムフェナクナトリウム水和物の分析結果を示している。表3及び表4の分析結果は、加速試験又は長期保存試験開始時の各化合物の含有量を100%として、試験開始後所定期間経過後における各化合物の含有量を%で示している。なお、この分析結果は、それぞれ3回の分析結果の平均値である。 (Results and discussion)
The results of the quantitative analysis are shown in Tables 3 and 4. Table 3 shows the analysis results of dry sodium sulfite, and Table 4 shows the analysis results of bromfenac sodium hydrate. The analysis results in Table 3 and Table 4 show the content of each compound in% after a predetermined period of time after the start of the test, assuming that the content of each compound at the start of the accelerated test or the long-term storage test is 100%. In addition, this analysis result is an average value of the analysis result of 3 times, respectively.
水性組成物(点眼剤)の乾燥亜硫酸ナトリウムの含有量と水性組成物の保存効力との関係性を、以下の試験により検討した。 4. Reference Test The relationship between the dry sodium sulfite content of the aqueous composition (eye drops) and the storage efficacy of the aqueous composition was examined by the following test.
実施例1における水性組成物を、40℃/25%RH以下または25℃/40%RHの条件に一定期間保存することで、乾燥亜硫酸ナトリウムの含有量が異なる7種の水性組成物とした。つぎに、これら水性組成物について、前述の保存効力試験と同様にして、S.aureusに対する保存効力試験を行った。また、乾燥亜硫酸ナトリウムの含有量は、前述の定量分析と同様にして定量した。 (Test method)
By storing the aqueous composition in Example 1 under the condition of 40 ° C./25% RH or less or 25 ° C./40% RH for a certain period, seven types of aqueous compositions having different dry sodium sulfite content were obtained. Then, these aqueous compositions were subjected to storage efficacy test against S. aureus in the same manner as the above-mentioned storage efficacy test. In addition, the content of dry sodium sulfite was quantified in the same manner as the aforementioned quantitative analysis.
試験の結果を図1に示す。図1は、水性組成物の乾燥亜硫酸ナトリウムの含有量(含有量0.2gを100%として、%で示す)をX軸に、水性組成物の保存効力(S.aureus接種7日後の対数減少値)をY軸にプロットしたグラフである。
図1に示されるように、水性組成物の乾燥亜硫酸ナトリウムの含有量と水性組成物の保存効力に正の相関が認められた(R2=0.9831)。この結果から、本化合物を含有する水性組成物において、乾燥亜硫酸ナトリウムの含有量を維持することで、その保存効力を維持できることがわかった。 (Test results and discussion)
The results of the test are shown in FIG. FIG. 1 shows the dry sodium sulfite content of the aqueous composition (in terms of content 0.2 g, expressed as 100%) on the X-axis, the storage efficacy of the aqueous composition (log reduction 7 days after S. aureus inoculation) Value) plotted on the Y axis.
As shown in FIG. 1, a positive correlation was observed between the dry sodium sulfite content of the aqueous composition and the storage efficacy of the aqueous composition (R 2 = 0.9831). From this result, it was found that the preservation efficacy can be maintained by maintaining the content of dry sodium sulfite in the aqueous composition containing the present compound.
以下に本化合物を用いた代表的な製剤例を示す。なお、下記製剤例において各成分の配合量は100mL中の含量である。 <Formulation example>
Hereinafter, representative formulation examples using the present compound are shown. In addition, the compounding quantity of each component is a content in 100 mL in the following formulation example.
本化合物 0.1g
ホウ酸 1.1g
ホウ砂 1.1g
エデト酸ナトリウム水和物 0.02g
ポビドン(K-30) 2g
乾燥亜硫酸ナトリウム 0.2g
ポリソルベート80 0.15g
ベンザルコニウム塩化物 0.005g
水酸化ナトリウム 適量
精製水 適量
pH 8.3 Formulation example 1
0.1 g of this compound
1.1 g of boric acid
Borax 1.1g
Edetate sodium hydrate 0.02 g
Povidone (K-30) 2g
Dry sodium sulfite 0.2g
Polysorbate 80 0.15 g
Benzalkonium chloride 0.005 g
Sodium hydroxide Appropriate amount Purified water Appropriate amount pH 8.3
本化合物 0.1g
ポリソルベート80 0.02g
ホウ酸 1.25g
ホウ砂 1.0g
エデト酸ナトリウム水和物 0.02g
ベンザルコニウム臭化物 0.0016g
塩酸 適量
水酸化ナトリウム 適量
精製水 適量
pH 8.3 Formulation example 2
0.1 g of this compound
Polysorbate 80 0.02 g
1.25 g of boric acid
Borax 1.0g
Edetate sodium hydrate 0.02 g
Benzalkonium bromide 0.0016g
Hydrochloric acid Appropriate amount Sodium hydroxide Appropriate amount Purified water Appropriate amount pH 8.3
本化合物 0.1g
ホウ酸 1.1g
ホウ砂 1.1g
エデト酸ナトリウム水和物 0.02g
ポビドン(K-30) 2g
乾燥亜硫酸ナトリウム 0.2g
ポリソルベート80 0.15g
ベンザルコニウム塩化物 0.001g
水酸化ナトリウム 適量
精製水 適量
pH 8.3 Formulation example 3
0.1 g of this compound
1.1 g of boric acid
Borax 1.1g
Edetate sodium hydrate 0.02 g
Povidone (K-30) 2g
Dry sodium sulfite 0.2g
Polysorbate 80 0.15 g
0.001 g of benzalkonium chloride
Sodium hydroxide Appropriate amount Purified water Appropriate amount pH 8.3
本化合物 0.1g
ホウ酸 1.1g
ホウ砂 1.1g
エデト酸ナトリウム水和物 0.02g
ポビドン(K-30) 2g
乾燥亜硫酸ナトリウム 0.2g
チロキサポール 0.02g
ベンザルコニウム塩化物 0.005g
水酸化ナトリウム 適量
精製水 適量
pH 8.3 Formulation example 4
0.1 g of this compound
1.1 g of boric acid
Borax 1.1g
Edetate sodium hydrate 0.02 g
Povidone (K-30) 2g
Dry sodium sulfite 0.2g
Tyloxapol 0.02g
Benzalkonium chloride 0.005 g
Sodium hydroxide Appropriate amount Purified water Appropriate amount pH 8.3
Claims (23)
- 点眼容器に収容された2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤であって、前記点眼容器が、さらに密閉包装されている、点眼剤。 An eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof accommodated in an eye drop container, wherein the eye drop container is further hermetically packaged.
- 脱酸素剤とともに密閉包装されている、請求項1記載の点眼剤。 The eye drop preparation according to claim 1, which is hermetically packaged together with the oxygen scavenger.
- 2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩の含有量が、0.05~0.2%(w/v)である、請求項1または2記載の点眼剤。 The eye drop according to claim 1 or 2, wherein the content of 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof is 0.05 to 0.2% (w / v).
- さらに、ベンザルコニウム塩を含有する、請求項1~3のいずれか一項に記載の点眼剤。 The eye drop preparation according to any one of claims 1 to 3, further comprising a benzalkonium salt.
- ベンザルコニウム塩が、ベンザルコニウム塩化物である、請求項4記載の点眼剤。 The eye drop preparation according to claim 4, wherein the benzalkonium salt is benzalkonium chloride.
- ベンザルコニウム塩の含有量が、0.0001~0.01%(w/v)である、請求項4または5記載の点眼剤。 The eye drop preparation according to claim 4 or 5, wherein the content of benzalkonium salt is 0.0001 to 0.01% (w / v).
- さらに、亜硫酸塩を含有する、請求項1~6のいずれか一項に記載の点眼剤。 The eye drop preparation according to any one of claims 1 to 6, further comprising a sulfite.
- 亜硫酸塩が、亜硫酸ナトリウムである、請求項7記載の点眼剤。 The eye drop preparation according to claim 7, wherein the sulfite is sodium sulfite.
- 亜硫酸塩の含有量が、0.01~0.5%(w/v)である、請求項7または8記載の点眼剤。 The eye drop preparation according to claim 7 or 8, wherein the sulfite content is 0.01 to 0.5% (w / v).
- さらに、ホウ酸、ホウ砂、エデト酸ナトリウム水和物、ポビドン、およびポリソルベート80を含有する、請求項1~9のいずれか一項に記載の点眼剤。 The eye drop preparation according to any one of claims 1 to 9, further comprising boric acid, borax, sodium edetate hydrate, povidone, and polysorbate 80.
- pHが、7.0~9.0である、請求項1~10のいずれか一項に記載の点眼剤。 The eye drop preparation according to any one of claims 1 to 10, wherein the pH is 7.0 to 9.0.
- ピロー袋に密閉包装されている、請求項1~11のいずれか一項に記載の点眼剤。 The eye drop preparation according to any one of claims 1 to 11, which is hermetically packaged in a pillow bag.
- ピロー袋がアルミフィルムからなる、請求項12記載の点眼剤。 The eye drop preparation according to claim 12, wherein the pillow bag is made of an aluminum film.
- ピロー袋の酸素透過度が20ml/m2・atm・24h以下である、請求項12または13記載の点眼剤。 The eye drop preparation according to claim 12 or 13, wherein the oxygen permeability of the pillow bag is 20 ml / m 2 · atm · 24 h or less.
- 脱酸素剤が、鉄系脱酸素剤である、請求項2~14のいずれか一項に記載の点眼剤。 The eye drop preparation according to any one of claims 2 to 14, wherein the oxygen scavenger is an iron-based oxygen scavenger.
- 2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤と、
前記点眼剤が収容された点眼容器と、
前記点眼容器を密閉した包装
とを含む、眼科用医薬製品。 An eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof;
An eye drop container containing the eye drop,
An ophthalmic pharmaceutical product, comprising: a package in which the eye drop container is sealed. - 包装が、さらに脱酸素剤を密閉している、請求項16記載の眼科用医薬製品。 The ophthalmic pharmaceutical product according to claim 16, wherein the package is further sealed with an oxygen scavenger.
- 2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤を、点眼容器に収容し、前記点眼容器をさらに密閉包装することを含む、眼科用医薬製品の製造方法。 A method for producing an ophthalmic pharmaceutical product, the method comprising containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof in an eye drop container and further hermetically packaging the eye drop container.
- 脱酸素剤とともに密閉包装する、請求項18記載の眼科用医薬製品の製造方法。 The method for producing an ophthalmic pharmaceutical product according to claim 18, which is hermetically packaged together with the oxygen scavenger.
- 2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤が収容された点眼容器を密閉した、包装。 A package in which an eye drop container containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof is sealed.
- さらに脱酸素剤を密閉した、請求項20記載の包装。 21. The package of claim 20 further sealed with an oxygen scavenger.
- 2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸またはその塩を含有する点眼剤を、点眼容器に収容し、前記点眼容器をさらに密閉包装すること含む、点眼剤の保存方法。 A method for storing eye drops, which comprises containing an eye drop containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof in an eye drop container and further hermetically packaging the eye drop container.
- 脱酸素剤とともに密閉包装する、請求項22記載の点眼剤の保存方法。 The method for preserving eye drops according to claim 22, which is hermetically packaged together with the oxygen scavenger.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019559202A JPWO2019117252A1 (en) | 2017-12-14 | 2018-12-13 | Eye drops containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a salt thereof |
CN201880080381.5A CN111712238A (en) | 2017-12-14 | 2018-12-13 | Eye drops containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or its salt |
KR1020207019902A KR20200099547A (en) | 2017-12-14 | 2018-12-13 | Eye drops containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or salt thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017-239669 | 2017-12-14 | ||
JP2017239669 | 2017-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019117252A1 true WO2019117252A1 (en) | 2019-06-20 |
Family
ID=66819287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/045895 WO2019117252A1 (en) | 2017-12-14 | 2018-12-13 | Eye drop containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid or salt thereof |
Country Status (4)
Country | Link |
---|---|
JP (1) | JPWO2019117252A1 (en) |
KR (1) | KR20200099547A (en) |
CN (1) | CN111712238A (en) |
WO (1) | WO2019117252A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114224830A (en) * | 2021-12-24 | 2022-03-25 | 辰欣药业股份有限公司 | Single-dose bacteriostatic-free ophthalmic preparation and preparation method thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102356603B1 (en) * | 2021-08-05 | 2022-02-08 | 지엘팜텍주식회사 | Ophthalmic composition containing recoflavone for dry eye syndrome |
WO2023014117A1 (en) * | 2021-08-05 | 2023-02-09 | 지엘팜텍주식회사 | Eye drop composition for treating dry eye syndrome containing recoflavone and method for preparing same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02124817A (en) * | 1988-01-27 | 1990-05-14 | Senju Pharmaceut Co Ltd | Treatment medicine of inflammatory ailment for local dosage |
JP2004123634A (en) * | 2002-10-03 | 2004-04-22 | Lion Corp | Ophthalmic composition |
JP2016522257A (en) * | 2013-06-19 | 2016-07-28 | センティス リサーチ センター | Stable bromfenac solution |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA966579B (en) * | 1995-08-04 | 1998-02-02 | Wakamoto Pharma Co Ltd | O/W emulsion composition for eye drops. |
CN103379904A (en) | 2011-01-18 | 2013-10-30 | 千寿制药株式会社 | Bromfenac aqueous liquid composition having preservative efficiency |
TWI604858B (en) * | 2012-03-28 | 2017-11-11 | 參天製藥股份有限公司 | Aqueous composition containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid and method of producing the same |
JP2015086222A (en) * | 2013-09-26 | 2015-05-07 | 参天製薬株式会社 | Stabilized 2-amino-3-(4-bromobenzoyl)phenylacetate-containing aqueous composition |
-
2018
- 2018-12-13 KR KR1020207019902A patent/KR20200099547A/en not_active Application Discontinuation
- 2018-12-13 JP JP2019559202A patent/JPWO2019117252A1/en active Pending
- 2018-12-13 CN CN201880080381.5A patent/CN111712238A/en active Pending
- 2018-12-13 WO PCT/JP2018/045895 patent/WO2019117252A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02124817A (en) * | 1988-01-27 | 1990-05-14 | Senju Pharmaceut Co Ltd | Treatment medicine of inflammatory ailment for local dosage |
JP2004123634A (en) * | 2002-10-03 | 2004-04-22 | Lion Corp | Ophthalmic composition |
JP2016522257A (en) * | 2013-06-19 | 2016-07-28 | センティス リサーチ センター | Stable bromfenac solution |
Non-Patent Citations (4)
Title |
---|
"Bronac Eye Drops (single dose) 0.5ml", 1 July 2017 (2017-07-01), XP055617690, Retrieved from the Internet <URL:http://www.druginfo.co.kr/cp/msdNew/detail/product_cp.aspx?cppid=224210&page1=1&page2=1> [retrieved on 20190207] * |
1 July 2017 (2017-07-01), XP055617692, Retrieved from the Internet <URL:http://go-b119.appspot.com/>650103071> * |
8 February 2019 (2019-02-08), XP055617689, Retrieved from the Internet <URL:https://nedrug.mfds.go.kr/index> * |
KIOS, 26 July 2017 (2017-07-26), XP055617693, Retrieved from the Internet <URL:http://www.kios.co.kr/kios/index.asp> [retrieved on 20190208] * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114224830A (en) * | 2021-12-24 | 2022-03-25 | 辰欣药业股份有限公司 | Single-dose bacteriostatic-free ophthalmic preparation and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
JPWO2019117252A1 (en) | 2020-12-17 |
CN111712238A (en) | 2020-09-25 |
KR20200099547A (en) | 2020-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019117252A1 (en) | Eye drop containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid or salt thereof | |
EP3171868B1 (en) | Packaged acetaminophen injection solution preparation | |
CA2415403C (en) | Method for obtaining aqueous formulations of oxidation-sensitive active principles | |
BRPI0913109B1 (en) | ophthalmic aqueous solution | |
JPH054918A (en) | Stable aqueous pharmaceutical | |
CA3093725C (en) | Epinephrine compositions and containers | |
PT1349580E (en) | Process to improve stability of a pharmaceutical composition | |
US20140303254A1 (en) | Process Of Manufacturing A Stable, Ready To Use Infusion Bag For An Oxidation Sensitive Formulation | |
JP6903448B2 (en) | Pharmaceutical composition containing dorzolamide and brimonidine | |
US20210401878A1 (en) | Stable Pharmaceutical Articles Containing Dilute Povidone Iodine Formulations | |
CN113318122B (en) | Disinfectant composition containing povidone iodine and application thereof | |
JP7317714B2 (en) | ophthalmic products | |
US20160143869A1 (en) | Stable bromfenac solution | |
JP2008120764A (en) | Prostaglandin aqueous ophthalmic solution | |
AU2017215419B2 (en) | Process of manufacturing a stable, ready to use infusion bag for an oxidation sensitive formulation | |
WO2014120293A1 (en) | Ophthalmic formulations | |
JP6877196B2 (en) | Preservative consisting of meglumine or its salt | |
TWI828025B (en) | Ophthalmic pharmaceutical composition with improved preservative effectiveness or light stability | |
JP6877613B2 (en) | Combination of preservative medicines | |
Velpandian | Preservatives for topical ocular drug formulations | |
JP6702754B2 (en) | Preservative containing dorzolamide | |
JP2019006753A (en) | Medicinal composition containing water-soluble thickening agent | |
TWI781268B (en) | Ophthalmic article and masking method | |
JP2020169213A (en) | Epinastine-containing eye drops | |
US20220105000A1 (en) | Stable parenteral dosage form of pyrazolone derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18888610 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019559202 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20207019902 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18888610 Country of ref document: EP Kind code of ref document: A1 |